Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach

Aniek J. G. Even*, Olga Hamming-Vrieze, Wouter van Elmpt, Veronique J. L. Winnepenninckx, Jolien Heukelom, Margot E. T. Tesselaar, Wouter V. Vogel, Ann Hoeben, Catharina M. L. Zegers, Danielle J. Vugts, Guus A. M. S. van Dongen, Harry Bartelink, Felix M. Mottaghy, Frank Hoebers, Philippe Lambin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)3870-3880
Number of pages11
JournalOncotarget
Volume8
Issue number3
DOIs
Publication statusPublished - 17 Jan 2017

Keywords

  • immuno-PET
  • Zirconium-89
  • cetuximab
  • LAHNSCC
  • EGFR
  • GROWTH-FACTOR RECEPTOR
  • CELL LUNG-CANCER
  • EGFR EXPRESSION
  • MACH-NC
  • CHEMOTHERAPY
  • SURVIVAL
  • RADIOTHERAPY
  • ZR-89
  • IMMUNOHISTOCHEMISTRY
  • METAANALYSIS

Cite this